An interventional study of Pulmonary vein reisolation and Ganglionic plexi ablation in Atrial Fibrillation (AF), Atrial Fibrillation Mechanisms and Catheter Ablation, sponsored by Barts & The London NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Barts & The London NHS Trust · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Atrial Fibrillation by Barts & The London NHS Trust — 6 open to participants now, 6 under way, none of them phase 3. Atrial Fibrillation · Barts & The London NHS Trust.
Among the 23 studies in Atrial Fibrillation by Barts & The London NHS Trust, this one is the 6th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2025, is one of 15 with no phase, and was the 22nd registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →6 of the 23 studies in Atrial Fibrillation by Barts & The London NHS Trust are open now, in 1 country. Recruiting first, the newest first:
Barts & The London NHS Trust · Sites in United Kingdom
Ages 18+
Barts & The London NHS Trust · Sites in United Kingdom
Ages 18–80 · Healthy volunteers
Barts & The London NHS Trust · Sites in United Kingdom
Ages 18–85
Barts & The London NHS Trust · Sites in United Kingdom
Ages 18+
Barts & The London NHS Trust · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 160 is close to the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 104 across the 20 interventional studies, 206 across the 3 observational. Of the 17 that completed or were terminated, 2 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
Barts & The London NHS Trust is the lead sponsor of 152 studies on the registry; 22 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
4 of the studies in Atrial Fibrillation by Barts & The London NHS Trust that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07574697Barts & The London NHS TrustAIC Genotyping Study | 2027-03-31 |
| NCT06096246Barts & The London NHS TrustInvestigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF) | 2027-07-26 |
| NCT05920824Barts & The London NHS TrustAtrial Functional Mitral Regurgitation and Tricuspid Regurgitation | 2027-08 |
| NCT05633303Barts & The London NHS TrustPersonalised Ablation Strategies in AF | 2027-10-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 23 studies in Atrial Fibrillation by Barts & The London NHS Trust, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Atrial fibrillation (AF) is the most common heart rhythm disorder, affecting millions worldwide and causing symptoms such as palpitations, fatigue and breathlessness. It also increases the risk of stroke and heart failure, so effective treatment is essential.
A treatment for AF involves catheter ablation, a minimally invasive procedure where problematic areas of the heart are targeted using controlled energy. This is done by passing wires called catheters, through blood vessels at the top of the leg all the way to the heart. However, this isn't effective for everyone and approximately half of patients experience a return of AF despite treatment.
In this researcher-led study at St Bartholomew's Hospital , the investigators will use a method called electroanatomical mapping to make a 3D picture of the left atrium, the heart's upper left chamber. To make this picture more detailed, information will be collected - such as how strong electrical signals are (voltage), how fast and in which direction they travel through the heart to describe abnormal areas and areas of scar within the heart. Information will also be gathered about the routes electricity takes and the nerve activity in the heart muscle. These detailed maps will help to understand why AF can continue indefinitely in some people, why ablation works for some people and not others, and improve how ablations are done to make them more effective.
All participants will undergo catheter ablation with these mapping methods integrated into the procedure. If AF recurs, patients will be invited for a second ablation targeting specific abnormal areas depending on the amount of scar found. This will be standardised across patients.
Patients will be followed for 12 months, with structured visits at 3, 6, 9 and 12 months and 48-hour ECG recorders at 6 and 12 months. By tracking how the heart's structure and electrical behaviour evolve, the aim is to to see if map-guided ablation reduces the need for further procedures, lowers healthcare costs and improves quality of life.
Ultimately, this study will provide clear, reproducible insights into AF mechanisms and yield practical guidance so clinicians can predict who will benefit from standard ablation treatment and who may require extra, map-guided treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
These are patients who've had recurrence of AF after their first ablation and less than 30% of their atria is comprised of low voltage zones. They will undergo autonomic ganglionic plexi site ablation combined with pulmonary vein re-isolation.
Procedure: Pulmonary vein reisolation · Procedure: Ganglionic plexi ablation
These are patients who've had recurrence of AF after their first ablation and greater than 30% of their atria is comprised of low voltage zones. They will undergo targeted ablation of conduction slowing sites in addition to ganlionic plexi site ablation and pulmonary vein reisolation.
Procedure: Pulmonary vein reisolation · Procedure: Ganglionic plexi ablation · Procedure: Substrate ablation
The pulmonary veins will be checked electrically and further ablation will be undertaken if they are not isolated.
Sites where ganglionix plexi have been found will be ablated.
Areas of rate dependent conduction velocity slowing will be targeted using cathether ablation
Assessment of Electrical, Structural and Autonomic Remodelling in Persistent Atrial Fibrillation
A primary objective of this study is to delineate the remodelling changes that occur in persistent atrial fibrillation and to utilise these to develop tailored ablation strategies.
Time frame: 4 years
Establish a Predictive Model to Idenitfy Which Patients are Responders to Pulmonary Vein Isolation Alone and Who Will Require Further Tailored Ablation Strategies
Based on clinical data approximately only 50% of patients with persistent atrial fibrillation who undergo pulmonary vein isolation remain in sinus rhythm. A main aim of the study is to develop a method to identify which patients will respond to pulmonary vein isolation alone and who will require further tailored ablation strategies.
Time frame: 24 months
To Assess if Ablation of Rate Dependent Conduction Velocity Slowing Sites Improves Freedom from Atrial Fibrillation
All patients who recur after their initial ablation will be invited to undergo a repeat ablation procedure. All patients will undergo ganglionic plexi ablation and reisolation their pulmonary veins. Those who have low voltage zones of more than 30% of their total left atrium will undergo further ablation of rate dependent conduction velocity slowing sites.
Time frame: 5 years
Develop Personalised Electrical Atrial Models
The data taken from the electrophysiological procedures will be used to create mathematical computer models that can be used as an environment to test electrophysiological theories and response to ablation.
Time frame: 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Nov 2029, 48 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 48 months is above that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Barts & The London NHS Trust →